Study Title

fusionpharmaceuticalsinc

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

Study Details

Description:

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 in participants with PSMA-positive mCRPC who have been previously treated with 177Lu-PSMA-617 or another 177Lu-PSMA radioligand therapy (RLT). The purpose of the dose optimization segment (Phase 2) is to determine the recommended FPI-2265 dose and regimen. Conclusions from Phase 2 will be based on safety, tolerability, and anti-tumor activity. Participants with PSMA positive scans will be randomized (1:1:1) to one of three different dosing arms: Arm 1: Will consist of nine doses of FPI-2265, administered every four weeks at 50 kBq/kg. Arm 2: Will consist of six doses of FPI-2265, administered every six weeks at 75 kBq/kg. Arm 3: Will consist of four doses of FPI-2265, administered every eight weeks at 100 kBq/kg. Participants will be monitored and assessed for efficacy response, disease progression and adverse events.

Contacts:

Fusion Pharma (N/A)

clinicaltrials@fusionpharma.com

1 (888) 506-4215

Inclusion
  • Participants with known BRCA mutations should have received FDA approved therapies ie PARP inhibitors per PI discretio
  • Positive PSMA PET/CT scan
  • Phase 2 ECOG performance status 0 or 1
  • Must have completed lutetium-PSMA therapy for more than 6 wks before first study drug dose
  • Progressive mCRPC
Exclusion
  • Participants who received more than two prior lines of cytotoxic chemo for CRPC
  • Participants with liver metastases will be excluded from Phase 2 of study.
  • Participants with skeletal metastases presented as a superscan on a Tc bone scan
  • Phase 2:Participants who progress within two cycles of prior treatment of 177Lu-PSMA therapy
  • No system cytotoxic, investigational therapy within 30 days of first dose. No large ext. beam radiotheapy for 4 wks.h

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided